

Press Release


Cipla announces Q1 FY1516 Unaudited Consolidated Financial Results


Mumbai, India, 14th Aug 2015: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited Consolidated Financial Results for the quarter ended Jun 30, 2015 (Q1).


Key Financial & Performance Highlights Q1 FY1516 vis-a-vis Q1 FY1415:

(Current year figures include the relevant results of Cipla's subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).

- Income from operations grew by 41.6% to Rs. 3,853 cr, up from Rs. 2,720 cr
- EBITDA grew by 91.8% to Rs. 1039 cr, up from Rs. 542 cr
- Profit after tax grew by 120.9% to Rs. 651 cr, up from Rs. 295 cr







Profit & Loss Highlights:

- Material cost is at 32.5% of income from operations in Q1 FY1516 as compared to 37.7% in Q1 FY1415
- EBIDTA as % of income from operations increased to 27% in Q1 FY1516 from 19.9% in Q1 FY1415
- Profit after tax grew by 120.9% to Rs. 651 cr, up from Rs. 295 cr in Q1 FY1415
- The results for the current period includes one-off revenue from the US market

Performance Review:

Domestic business:

- Domestic sales grew by 8.4% to Rs. 1,397 cr during Q1 FY1516, up from Rs. 1,289 cr during Q1 FY1415
- The growth in domestic sales was largely on account of growth in Respiratory, Anti-infectives, Cardiac and Gastro Intestinal therapies

International business:

- Exports of formulations increased by 78.5% to Rs. 2,174 cr during Q1 FY1516, from Rs. 1,218 cr during Q1 FY1415.
- Exports of APIs increased by 47% to Rs. 206 cr during Q1 FY1516, from Rs. 140 cr during Q1 FY1415.

About Cipla:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Cipla's portfolio includes over 1500 products in various therapeutic categories with one quality standard globally. Cipla's turnover in 2014/15 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Media Contacts:

Investor Relations

Anant Atal Contact No.: 022 – 24826450

E-Mail: anant.atal@cipla.com

Corporate Communications

Pallavi Golar

Contact No.: +91 9833641788 E Mail: pallavi.golar@cipla.com